Systematic Review
. 2019 Oct; 20(1):62.
doi: 10.1186/s40360-019-0339-1.

Aromatase inhibitors and risk of cardiovascular events in breast cancer patients: a systematic review and meta-analysis

Yang He 1 Jianhua Zhang 2 Guofang Shen 3 Lin Liu 1 Qingwei Zhao 1 Xiaoyang Lu 1 Hongyu Yang 4 Dongsheng Hong 5 
Affiliations
  • PMID: 31665091
  •     66 References
  •     1 citations

Abstract

Background: Cardiovascular events (CVEs) was considered as one of the primary cause to reduce the quality of life in breast cancer patients with aromatase inhibitors (AIs) treatment, which has not been sufficiently addressed. The aim of this study was to assess the correlation between risk of CVEs and AIs in patients with breast cancer.

Methods: Included studies were obtained from the databases of Embase, Pubmed, Cochrane Library, Clinical Trials.gov, and reference lists. The main outcome measures were overall incidence, odds ratios (ORs), and 95% confidence intervals (CIs). Furthermore, the association and the risk differences among different tumor types, AIs,ages,or treatment regimens were conducted. Fixed-effect or random-effect models were applied in the statistical analyses according to the heterogeneity. Our analysis was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Results: Seventeen studies, which included 44,411 subjects, were included in our analyses. The overall incidence of CVEs in AIs group was 13.02% (95% CI: 8.15-20.17%) and almost all of the high-grade CVEs occurred in patients treated with AIs. The pooled ORs of CVEs was 0.9940 (95% CI: 0.8545-1.1562). Under sub-group analysis, the incidence of CVEs related to exemestane was higher than that of controls (OR = 1.1564, 95% CI: 1.0656-1.2549), but no statistical differences in risk of CVEs were found in other sub-group analysis. No evidence of publication bias was found for incidence of CVEs in our meta-analysis by a funnel plot.

Conclusions: These results suggest that patients with breast cancer treated with AIs do not have a significant risk of developing CVEs in comparison with the controls, and exemestane might not be considered as the alternative AI to the breast cancer patients from the perspective of CVEs. Further studies are recommended to investigate this association and the risk differences among different tumor types, AIs or treatment regimens.

Keywords: Aromatase inhibitors; Breast cancer; Cardiovascular events; Meta-analysis.

Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
Aleli Campbell, Rosalinda Heydarian, +2 authors, Zeina A Nahleh.
Breast J, 2018 Feb 15; 24(3). PMID: 29442401
Multifaceted Role of Pneumolysin in the Pathogenesis of Myocardial Injury in Community-Acquired Pneumonia.
Ronald Anderson, Jan G Nel, Charles Feldman.
Int J Mol Sci, 2018 Apr 12; 19(4). PMID: 29641429    Free PMC article.
Review.
Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study.
Manfred Kaufmann, Walter Jonat, +4 authors, Gunter von Minckwitz.
J Clin Oncol, 2007 Jun 15; 25(19). PMID: 17563395
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial.
R C Coombes, L S Kilburn, +32 authors, Intergroup Exemestane Study.
Lancet, 2007 Feb 20; 369(9561). PMID: 17307102
Highly Cited.
The pathophysiology of myocardial infarction-induced heart failure.
Daniele Gabriel-Costa.
Pathophysiology, 2018 Apr 25; 25(4). PMID: 29685587
Review.
Effects of high-intensity interval training on vascular function in breast cancer survivors undergoing anthracycline chemotherapy: design of a pilot study.
Kyuwan Lee, Irene Kang, +5 authors, Christina M Dieli-Conwright.
BMJ Open, 2018 Jul 02; 8(6). PMID: 29961039    Free PMC article.
[Summary of the ESC position paper on cancer treatment and cardiovascular toxicity].
J Hoog, S Achenbach.
Herz, 2016 Nov 11; 41(8). PMID: 27830273
Review.
Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis.
Ankle Brachial Index Collaboration, F G R Fowkes, +47 authors, M M McDermott.
JAMA, 2008 Jul 10; 300(2). PMID: 18612117    Free PMC article.
Highly Cited. Review.
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial.
E Munzone, A Giobbie-Hurder, +13 authors, International Breast Cancer Study Group and the BIG 1-98 Collaborative Group.
Ann Oncol, 2015 Sep 21; 26(12). PMID: 26387144    Free PMC article.
Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.
Eitan Amir, Bostjan Seruga, +2 authors, Alberto Ocaña.
J Natl Cancer Inst, 2011 Jul 12; 103(17). PMID: 21743022
Highly Cited. Systematic Review.
Cardiovascular Protective Effects and Clinical Applications of Resveratrol.
Sanghyun Cho, Kyung Namkoong, +6 authors, Jin Han.
J Med Food, 2017 Mar 28; 20(4). PMID: 28346848
Review.
A meta-analysis of randomized controlled trials comparing the efficacy and safety of anastrozole versus tamoxifen for breast cancer.
Yan Yang, Wei Pan, +2 authors, Xinchen Sun.
Oncotarget, 2017 Apr 19; 8(29). PMID: 28415634    Free PMC article.
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial.
Vivianne C G Tjan-Heijnen, Irene E G van Hellemond, +14 authors, Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators.
Lancet Oncol, 2017 Oct 17; 18(11). PMID: 29031778
Safety of aromatase inhibitor therapy in breast cancer.
Anneleen Lintermans, Patrick Neven.
Expert Opin Drug Saf, 2015 Jun 11; 14(8). PMID: 26059833
Review.
Everolimus Plus Letrozole for Treatment of Patients With HR+, HER2- Advanced Breast Cancer Progressing on Endocrine Therapy: An Open-label, Phase II Trial.
Tamar Safra, Bella Kaufman, +5 authors, Rinat Yerushalmi.
Clin Breast Cancer, 2017 Nov 04; 18(2). PMID: 29097108
Understanding cardiovascular injury after treatment for cancer: an overview of current uses and future directions of cardiovascular magnetic resonance.
Sujethra Vasu, W Gregory Hundley.
J Cardiovasc Magn Reson, 2013 Aug 02; 15. PMID: 23902649    Free PMC article.
Review.
Cardiotoxicity associated with radiotherapy in breast cancer: A question-based review with current literatures.
Qian Zhu, Youlia M Kirova, +2 authors, Jiayi Chen.
Cancer Treat Rev, 2018 May 20; 68. PMID: 29777800
Review.
Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet, 2015 Jul 28; 386(10001). PMID: 26211827
Highly Cited.
Incidence of major complications after percutaneous native renal biopsies in adults from low-income to middle-income countries: a protocol for systematic review and meta-analysis.
Shepherd Kajawo, Mothusi Walter Moloi, +3 authors, Ikechi G Okpechi.
BMJ Open, 2018 Apr 29; 8(4). PMID: 29703858    Free PMC article.
A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer.
Hiroji Iwata, Norikazu Masuda, +10 authors, Shinzaburo Noguchi.
Breast Cancer Res Treat, 2013 May 30; 139(2). PMID: 23715630    Free PMC article.
Mother-to-child transmission of HIV infection and its associated factors in Ethiopia: a systematic review and meta-analysis.
Getachew Mullu Kassa.
BMC Infect Dis, 2018 May 12; 18(1). PMID: 29747581    Free PMC article.
Systematic Review.
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
Robert J Paridaens, Luc Y Dirix, +6 authors, Patrick Therasse.
J Clin Oncol, 2008 Sep 17; 26(30). PMID: 18794551    Free PMC article.
Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry.
Jaime L Peters, Alex J Sutton, +2 authors, Lesley Rushton.
J Clin Epidemiol, 2008 Jun 10; 61(10). PMID: 18538991
Highly Cited.
Long-term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and meta-analysis.
Partha Sardar, Amartya Kundu, +6 authors, Carl J Lavie.
Clin Cardiol, 2017 Mar 01; 40(2). PMID: 28244595    Free PMC article.
Systematic Review.
Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
Paul E Goss, James N Ingle, +18 authors, Lois E Shepherd.
J Clin Oncol, 2013 Jan 30; 31(11). PMID: 23358971    Free PMC article.
Highly Cited.
Cardiovascular Disease After Aromatase Inhibitor Use.
Reina Haque, Jiaxiao Shi, +6 authors, Rowan T Chlebowski.
JAMA Oncol, 2016 Apr 22; 2(12). PMID: 27100398
Reporting of coronary artery calcification on chest CT studies in breast cancer patients at high risk of cancer therapy related cardiac events.
William J Phillips, Christopher Johnson, +8 authors, Gary R Small.
Int J Cardiol Heart Vasc, 2018 May 12; 18. PMID: 29750180    Free PMC article.
Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Meta-analysis of randomized trials.
Federica Cuppone, Emilio Bria, +8 authors, Diana Giannarelli.
Cancer, 2007 Nov 28; 112(2). PMID: 18041059
Cardiotoxicity of aromatase inhibitors and tamoxifen in postmenopausal women with breast cancer: a systematic review and meta-analysis of randomized controlled trials.
F Khosrow-Khavar, K B Filion, +4 authors, L Azoulay.
Ann Oncol, 2016 Dec 22; 28(3). PMID: 27998966    Free PMC article.
Systematic Review.
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
R Charles Coombes, Emma Hall, +24 authors, Intergroup Exemestane Study.
N Engl J Med, 2004 Mar 12; 350(11). PMID: 15014181
Highly Cited.
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
Francesco Boccardo, Alessandra Rubagotti, +17 authors, Piero Sismondi.
J Clin Oncol, 2005 Jul 13; 23(22). PMID: 16009955
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines:  The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
Jose Luis Zamorano, Patrizio Lancellotti, +14 authors, ESC Scientific Document Group.
Eur Heart J, 2016 Aug 28; 37(36). PMID: 27567406
Highly Cited.
Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Mariana L Henry, Jiangong Niu, +2 authors, Mariana Chavez-MacGregor.
JACC Cardiovasc Imaging, 2018 Aug 11; 11(8). PMID: 30092967    Free PMC article.
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial.
Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, John F Forbes, +4 authors, Michael Baum.
Lancet Oncol, 2007 Dec 18; 9(1). PMID: 18083636
Highly Cited.
Cardiovascular Disease and Breast Cancer: Where These Entities Intersect: A Scientific Statement From the American Heart Association.
Laxmi S Mehta, Karol E Watson, +10 authors, American Heart Association Cardiovascular Disease in Women and Special Populations Committee of the Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research.
Circulation, 2018 Feb 14; 137(8). PMID: 29437116    Free PMC article.
Highly Cited. Systematic Review.
Meta-analysis of serum lactate dehydrogenase and prognosis for osteosarcoma.
Yucheng Fu, Tao Lan, +2 authors, Wei Yu.
Medicine (Baltimore), 2018 May 10; 97(19). PMID: 29742740    Free PMC article.
Review.
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
Gabe S Sonke, Lowell L Hart, +16 authors, Howard A Burris.
Breast Cancer Res Treat, 2017 Oct 24; 167(3). PMID: 29058175    Free PMC article.
The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis.
Naqash J Sethi, Joshua Feinberg, +3 authors, Janus C Jakobsen.
PLoS One, 2017 Oct 27; 12(10). PMID: 29073191    Free PMC article.
Systematic Review.
Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group.
A U Buzdar, W Jonat, +8 authors, D Lee.
Cancer, 1998 Sep 18; 83(6). PMID: 9740079
Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis.
Tina Didari, Shilan Mozaffari, Shekoufeh Nikfar, Mohammad Abdollahi.
World J Gastroenterol, 2015 Mar 18; 21(10). PMID: 25780308    Free PMC article.
Highly Cited. Systematic Review.
Meta-analysis of vascular and neoplastic events associated with tamoxifen.
R Scott Braithwaite, Rowan T Chlebowski, +3 authors, Nananda F Col.
J Gen Intern Med, 2003 Dec 23; 18(11). PMID: 14687281    Free PMC article.
Factors associated with advanced hepatic fibrosis in patients with various internal diseases: A multicenter community-based survey.
Takumi Kawaguchi, Tetsuaki Inokuchi, +8 authors, Takuji Torimura.
Hepatol Res, 2018 May 08; 48(11). PMID: 29736951
Cardiovascular Risk Factors and Breast Cancer.
Thomas P Houston, Jamie S Ostroff.
J Clin Oncol, 2018 Jul 24; 36(27). PMID: 30036116
Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study.
Jennifer L Patnaik, Tim Byers, +2 authors, Thomas D Denberg.
Breast Cancer Res, 2011 Jun 22; 13(3). PMID: 21689398    Free PMC article.
Highly Cited.
Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis.
Hermann Brenner.
Lancet, 2002 Oct 22; 360(9340). PMID: 12387961
Highly Cited.
Associations between adjuvant radiotherapy and different causes of death in a German breast cancer cohort.
Nadia Obi, Christine Eulenburg, +5 authors, Dieter Flesch-Janys.
Breast, 2017 Dec 19; 38. PMID: 29248876
Relationship between carotid or coronary artery calcification and osteoporosis in the elderly.
Jie Zhu, Feng Guo, Jie Zhang, Chunli Mu.
Minerva Med, 2018 Apr 27; 110(1). PMID: 29696936
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
David Moher, Alessandro Liberati, +2 authors, PRISMA Group.
BMJ, 2009 Jul 23; 339. PMID: 19622551    Free PMC article.
Highly Cited.
High-grade proteinuria as a cardiovascular risk factor in renal transplant recipients.
O Guliyev, B Sayin, +5 authors, M Haberal.
Transplant Proc, 2015 Jun 04; 47(4). PMID: 26036546
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
Wei-xiang Qi, Zan Shen, +5 authors, Yang Yao.
Br J Clin Pharmacol, 2012 Aug 14; 75(4). PMID: 22882307    Free PMC article.
Systematic Review.
Cardiac Arrhythmia Classification by Multi-Layer Perceptron and Convolution Neural Networks.
Shalin Savalia, Vahid Emamian.
Bioengineering (Basel), 2018 May 08; 5(2). PMID: 29734666    Free PMC article.
Assessment and management of bone health in women with oestrogen receptor-positive breast cancer receiving endocrine therapy: Position statement of the Endocrine Society of Australia, the Australian and New Zealand Bone & Mineral Society, the Australasian Menopause Society and the Clinical Oncology Society of Australia.
Mathis Grossmann, Sabashini K Ramchand, +5 authors, Helena Teede.
Clin Endocrinol (Oxf), 2018 May 10; 89(3). PMID: 29741296
Review.
The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer.
Achim Wöckel, Ute-Susann Albert, +3 authors, Tanja Stüber.
Dtsch Arztebl Int, 2018 May 29; 115(18). PMID: 29807560    Free PMC article.
Systematic Review.
A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy.
Mariana S Sousa, Michelle Peate, +2 authors, Michael Friedlander.
Ther Adv Med Oncol, 2017 May 12; 9(4). PMID: 28491147    Free PMC article.
Review.
Clinical practice guidelines in breast cancer.
N Kumar Tyagi, S Dhesy-Thind.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910658    Free PMC article.
Review.
Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide.
Mauro Feola, Ornella Garrone, +6 authors, Marco Merlano.
Int J Cardiol, 2009 Dec 01; 148(2). PMID: 19945181
Competing mortality risks among women aged 50-79 years when diagnosed with invasive breast cancer, Queensland, 1997-2012.
Paramita Dasgupta, Joanne F Aitken, Christopher Pyke, Peter D Baade.
Breast, 2018 Jul 22; 41. PMID: 30029053
Breast cancer as a global health concern.
Steven S Coughlin, Donatus U Ekwueme.
Cancer Epidemiol, 2009 Nov 10; 33(5). PMID: 19896917
Highly Cited. Review.
Cardiovascular Effects of Chemotherapy Used in the Treatment of Breast Cancers.
Raquel N Rozner, William H Frishman.
Cardiol Rev, 2018 Jul 28; 27(2). PMID: 30052537
Review.
Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women.
Adnan Aydiner.
Breast, 2013 Mar 07; 22(2). PMID: 23462682
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
Joyce O'Shaughnessy, Katarina Petrakova, +12 authors, Gabriel N Hortobagyi.
Breast Cancer Res Treat, 2017 Nov 23; 168(1). PMID: 29164421    Free PMC article.
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.
Ian Smith, Denise Yardley, +14 authors, Joyce O'Shaughnessy.
J Clin Oncol, 2017 Jan 24; 35(10). PMID: 28113032
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
Alan S Coates, Aparna Keshaviah, +17 authors, Aron Goldhirsch.
J Clin Oncol, 2007 Jan 04; 25(5). PMID: 17200148
Highly Cited.
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
M Baum, A Buzdar, +5 authors, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
Cancer, 2003 Oct 30; 98(9). PMID: 14584060
Highly Cited.
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.
Marco Colleoni, Weixiu Luo, +30 authors, SOLE Investigators.
Lancet Oncol, 2017 Nov 22; 19(1). PMID: 29158011
Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial.
Cornelis J H van de Velde, Daniel Rea, +14 authors, Stephen E Jones.
Lancet, 2011 Jan 21; 377(9762). PMID: 21247627
Highly Cited.
Aromatase Inhibitors-Induced Musculoskeletal Disorders: Current Knowledge on Clinical and Molecular Aspects.
Sara Tenti, Pierpaolo Correale, +2 authors, Luigi Pirtoli.
Int J Mol Sci, 2020 Aug 13; 21(16). PMID: 32781535    Free PMC article.
Review.